- 3TC (lamivudine, Epivir)
- Abacavir (Ziagen)
- Atazanavir (Reyataz)
- Atripla
- AZT (zidovudine, Retrovir)
- Combivir
- d4T (stavudine, Zerit)
- Darunavir (Prezista)
- ddI (didanosine, Videx / VidexEC)
- Efavirenz (Sustiva)
- Fosamprenavir (Telzir)
- FTC (emtricitabine, Emtriva)
- Indinavir (Crixivan)
- Kaletra
- Kivexa
- Lopinavir
- Nelfinavir (Viracept)
- Nevirapine (Viramune)
- Ritonavir (Norvir)
- Saquinavir (Invirase)
- T-20 (enfuvirtide, Fuzeon)
- Tenofovir disoproxil (Viread)
- Tipranavir (Aptivus)
- Trizivir
- Truvada
Lopinavir
Lopinavir is a protease inhibitor that is manufactured by Abbott Laboratories. Protease inhibitors block the activity of the HIV protease (or proteinase) enzyme to slow HIV replication and delay damage to the immune system. During development, lopinavir was known as ABT-378.
Lopinavir must be taken with a low dose of ritonavir (Norvir), to slow the body’s processing of lopinavir boosts blood levels of the drug. This enhances the antiviral effect of lopinavir. Since Abbott manufactures both lopinavir and ritonavir, lopinavir is only available in combination with ritonavir. This combination is marketed as Kaletra.
For more information on lopinavir and Kaletra, see Kaletra.
latest aidsmap news
- 'ART as prevention tool' policy announced for British Columbia
- <i>The Lancet</i>: HIV is a global disaster
- Important changes to nevirapine dosing advice made by FDA
- Fatty liver in patients with HIV associated with metabolic abnormalities
- Most HIV infections in Zambia and Rwanda happen in marriage: prevention programmes for couples recommended
- HIV-positive Caribbean people in the UK experience high levels of stigma
- Poverty and unemployment common amongst HIV-positive Londoners
- Risk of death for people with HIV now similar to that seen in the general population
- Simple, cheap test an accurate measure of hardening of the arteries in patients with HIV
- Asymptomatic anal HPV infection more common than thought in heterosexual men
